Challenges of thyroid cancer management in amiodarone-treated patients: a case report

Authors

  • Mirela Sanda Petrulea
  • Codruta Lencu
  • Doina Piciu
  • Cosmin Ioan Lisencu
  • Carmen Emanuela Georgescu

DOI:

https://doi.org/10.15386/cjmed-502

Keywords:

thyroid cancer, amiodarone, lymph nodes dissection, radioiodine

Abstract

 

Abstract

 

Thyroid carcinoma (TC) is the most common endocrine malignancy. Although the overall prognosis for patients with TC is good, up to 20-30% of patients have recurrent or persistent disease after conventional therapy by surgical resection and radioactive iodine (RAI).Amiodarone is a highly efficient anti-arrhythmic drug with a very long half-life, so it may interfere with RAI many months after the drug withdrawal.This case report mirrors the challenges of thyroid cancer management in an amiodarone-treated patient.

 

Author Biographies

Mirela Sanda Petrulea, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Department of Endocrinology

Codruta Lencu, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Department of Endocrinology

Doina Piciu, Ion Chiricuta Institute of Oncology, Cluj-Napoca,

Nuclear Medicine Department

Cosmin Ioan Lisencu, Ion Chiricuta Institute of Oncology, Cluj-Napoca,

Surgery Department

Carmen Emanuela Georgescu, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca

Department of Endocrinology

Downloads

Additional Files

Published

2015-09-28

How to Cite

1.
Petrulea MS, Lencu C, Piciu D, Lisencu CI, Georgescu CE. Challenges of thyroid cancer management in amiodarone-treated patients: a case report. Med Pharm Rep [Internet]. 2015 Sep. 28 [cited 2025 Oct. 3];88(4):550-4. Available from: https://medpharmareports.com/index.php/mpr/article/view/502

Issue

Vol. 88 No. 4 (2015)

Section

Case Report

License

The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.

 Creative Commons License
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.